top of page

Strategic Alternatives Create Their Own Constraints

  • eric74595
  • Apr 2
  • 2 min read

Once a strategic alternatives process begins, optionality narrows quickly. What starts as an open exploration of paths forward — partnerships, capital raises, divestitures, mergers — rapidly becomes a constrained decision environment where governance discipline matters more than at any other time.

The Paradox of Strategic Alternatives

The term strategic alternatives implies breadth — a deliberate assessment of all available options. In practice, the process creates its own momentum. Once advisors are engaged, data rooms are populated, and potential counterparties are contacted, the company has entered a process that is difficult to pause and even more difficult to reverse. Internal stakeholders begin positioning around expected outcomes. Market signals, if the process becomes known, begin to price in assumptions.

Having led a strategic alternatives process at a publicly traded medical device company, I have experienced this dynamic firsthand. The board's options, which seemed expansive at the outset, narrowed materially as the process advanced. Each step forward closed doors that had been open weeks before.

Governance Before the Process Begins

This is why governance discipline matters most before paths are publicly or internally constrained. The decisions that shape the process — when to engage, whom to include, what criteria to apply, and what outcomes are acceptable — are governance decisions that deserve the same rigor as the transaction itself. A board that defers these decisions, or delegates them entirely to management or advisors, risks losing control of the very process it authorized.

Practical Implications

For boards and CEOs considering a strategic alternatives process, the key insight is that preparation and governance structure should precede the formal launch. Define success criteria before engaging advisors. Align the board on acceptable outcomes before contacting counterparties. And maintain the discipline to pause or redirect the process if circumstances change — because once the process has momentum, the cost of changing course increases exponentially.

Recent Posts

See All
Diligence Is About Risk, Not Just Valuation

Transaction diligence in regulated medical technology environments is less about financial modeling and more about identifying where risk resides — technically, operationally, and organizationally. Ye

 
 
 

Comments


Heinz Ventures Logo (White)
  • Heinz Ventures on LinkedIn

The content on this website is provided for general informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities or other financial instruments. Nothing on this website should be relied upon as investment advice or as a basis for any investment decision.

Professional services described on this website are provided independently of any investment-related activities and are subject to applicable conflict checks and engagement terms.  Any investment-related information is provided, if at all, solely in private communications and to qualified parties.

©2026 by Heinz Ventures, LLC. All Rights Reserved.

bottom of page